Cempra Pharmaceuticals, Inc. to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

CHAPEL HILL, N.C., Feb. 9, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc., a company focused on the development of differentiated antibiotics, today announced thatPrabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference at 8:30 a.m. EST, February 14, 2011, at the Waldorf-Astoria Hotel in New York City. Dr. Fernandes will provide an overview of the company’s two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia, and TAKSTA, an orally-administered treatment for acute bacterial skin and skin structure infections (aBSSSI) including methicillin-resistant Staphylococcus aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products’ lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

SOURCE Cempra Pharmaceuticals Inc.